These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15198465)

  • 1. New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?
    Awad AG; Voruganti LN
    Can J Psychiatry; 2004 May; 49(5):297-302. PubMed ID: 15198465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance.
    Lambert M; Schimmelmann BG; Karow A; Naber D
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S181-90. PubMed ID: 14677077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2013 Aug; 27(8):625-36. PubMed ID: 23757184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.
    Awad AG
    CNS Drugs; 2019 Jan; 33(1):1-8. PubMed ID: 30511350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation antipsychotics: looking beyond efficacy.
    Awad AG
    Can J Psychiatry; 2004 May; 49(5):283-4. PubMed ID: 15198462
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic dysphoria: towards a new synthesis.
    Voruganti L; Awad AG
    Psychopharmacology (Berl); 2004 Jan; 171(2):121-32. PubMed ID: 14647964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subjective experiences on antipsychotic medications: synthesis and conclusions.
    Marder SR
    Acta Psychiatr Scand Suppl; 2005; (427):43-6. PubMed ID: 15877721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics.
    Kilian R; Dietrich S; Toumi M; Angermeyer MC
    Acta Psychiatr Scand; 2004 Aug; 110(2):108-18. PubMed ID: 15233711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients' subjective experiences of antipsychotics: clinical relevance.
    Hellewell JS
    CNS Drugs; 2002; 16(7):457-71. PubMed ID: 12056921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relationships between positive or negative early subjective response to antipsychotics and demographic and clinical variables in the group of patients with schizophrenia].
    Murawiec S
    Psychiatr Pol; 2005; 39(6):1185-98. PubMed ID: 16526184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
    Misdrahi D; Llorca PM; Lançon C; Bayle FJ
    Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia.
    Jaffe AB; Levine J
    J Clin Psychiatry; 2003; 64 Suppl 17():3-6. PubMed ID: 14680419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life.
    Staring AB; Mulder CL; Duivenvoorden HJ; De Haan L; Van der Gaag M
    Schizophr Res; 2009 Aug; 113(1):27-33. PubMed ID: 19525092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication adherence and subjective weight perception in patients with first-episode psychotic disorder.
    Wong MM; Chen EY; Lui SS; Tso S
    Clin Schizophr Relat Psychoses; 2011 Oct; 5(3):135-41. PubMed ID: 21983497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.